2016 Cell Based Assays Molecular Biology Small Molecule 
Drug Discovery World
JULY 25, 2022
OMass retains biological complexity and interrogates this complexity at high-resolution to gain insights invisible to cell-based assays and stripped-out of traditional cell-free approaches. Native MS can detect specific interactions that are too weak to induce detectable activity in cell-based assays.
Elrig
APRIL 29, 2024
Fascinated by the potential of AI in medical research, I transitioned to BenevolentAI in early 2023 as a Biology Project Leader. There, I supported AI-enabled DD efforts in their small molecule portfolio. Driven by an interest in drug discovery Millie joined AstraZeneca after completion of her PhD at the end of 2020.
Expert insights. Personalized for you.
130 
Let's personalize your content